Article · 30 Apr 2025
OtherPublished 22 Jul 2016
Cancer therapy with Newcastle disease virus: rationale for new immunotherapeutic combinations
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Cancer immunotherapy with Newcastle disease virus (NDV) dates back to 1960s, when intratumoral treatment of a cervical cancer patient was noted to result in an abscopal effect with distant tumor regression. Since then, multiple preclinical and clinical studies have demonstrated the inherent ability of NDV to increase immunogenicity of tumor cells. Recently, these properties were explored in animal models within the context of novel immunotherapies such as antibodies targeting immune checkpoints, with demonstration of induction of systemic antitumor immunity and regression of tumors not directly affected by the virus. These studies highlight the immunotherapeutic potential of NDV and provide a strong rationale for exploration of NDV and perhaps other oncolytic viruses in combination with immunomodulatory antibodies in the clinic.
Subjects
General & Internal MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Clinical Investigation.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinical Investigation
- SubjectGeneral & Internal Medicine
- BylineArticles whose byline prints “Tamar Plitt”
- BylineArticles whose byline prints “Dmitriy Zamarin”